


VENUS

#ACC20/#WCCardio



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Patients with persistent AF were randomized in a 1:1.15 single-blind fashion to either catheter ablation + vein of Marshall (VOM) ablation vs. standard catheter ablation. Patients were followed for 12 months.



RESULTS

- Primary endpoint, freedom from AT/AF ≥ 30 seconds after 3 months, VOM ablation + catheter ablation vs. standard catheter ablation: 49.2% vs. 38% ($p = 0.037$)
- Freedom from AT/AF at 90 days: 62.2% vs. 53.8% ($p = 0.09$); zero AT/AF on 6- and 12-month monitoring: 76.1% vs. 67.8% ($p = 0.029$)
- Total procedure time: 215.9 vs. 190.3 minutes ($p = 0.001$)

CONCLUSIONS

- This single-center, single-blind trial indicates that concomitant VOM alcohol ablation among patients with persistent AF undergoing catheter ablation is superior to standard catheter ablation alone
- These are important findings and will need to be validated in larger studies

Presented by Dr. Miguel Valderrábano at ACC.20/WCC